We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Amicus Therapeutics

News List

Amicus Opens Philly CoE contractpharma
March 06, 2020
Amicus Therapeutics has opened the company’s Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia, PA, to advance its portfolio of rare disease gene therapy programs.
Amicus Therapeutics expands gene therapy alliance with Penn pharmaceutical-technology
May 31, 2019
Amicus Therapeutics has expanded its research and development (R&D) alliance with the Perelman School of Medicine at the University of Pennsylvania (Penn).
Amicus’ Galafold receives TGA approval for Fabry disease treatment in Australia pharmaceutical-technology
August 17, 2017
Amicus Therapeutics has received the Australian Therapeutic Goods Administration (TGA) approval for Galafold (Migalastat) to treat patients with Fabry disease (alpha-galactosidase A deficiency) in the country.